-
-
-
-
-
-
-
Chardan Reiterates Buy Rating on Arbutus Biopharma (ABUS) Following Moderna Settlement
-
-
-
-
-
-
-
Arbutus Biopharma (ABUS) Tops Q2 EPS by 5c
-
-
-
-
-
-
-
Arbutus Biopharma (ABUS) and Barinthus Bio (BRNS) Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
-
-
-
-
447,355 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

